Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency

Pharmaceutical Investing

Midatech (Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for its advanced liver cancer drug candidate MTD119. As quoted in the press release: MTD119 (previously MTR104) is a treatment for hepatocellular carcinoma (HCC), a …

Midatech (Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for its advanced liver cancer drug candidate MTD119.

As quoted in the press release:

MTD119 (previously MTR104) is a treatment for hepatocellular carcinoma (HCC), a rare, aggressive cancer that affects the liver. There are very few treatments for HCC, particularly for patients with an advanced form of the disease, and fewer than ten per cent of patients with HCC currently survive beyond five years of diagnosis. MTD119 is a combination of Midatech’s gold nanoparticle (GNP) technology with the potent anti-tubulin chemotherapeutic maytansine, in which the GNP is designed to improve the biodistribution and targeted delivery of the maytansine agent to the tumour site.

Click here to read the full press release.

The Conversation (0)
Ă—